Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332774 · ClinicalTrials.gov registry record · Phase 3
Nevanac 3-Month Safety Study With QID Dosing
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 149
- Enrollment target
NCT00332774 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 149 participants.
The verdict
NCT00332774, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 149 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.
Interventions
- DRUG Nepafenac ophthalmic solution 0.1%
- DRUG Ketorolac Tromethamine ophthalmic solution 0.4%
- OTHER Nepafenac ophthalmic suspension vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00332774
The ClinicalTrials.gov registry entry for NCT00332774 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nepafenac ophthalmic solution 0.1% is the first listed.
NCT00332774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00332774 about?
NCT00332774 is a clinical study titled "Nevanac 3-Month Safety Study With QID Dosing". The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.
What is the current status of trial NCT00332774?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 149 participants. The study started on 2006-02. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00332774?
The interventions under investigation include: Nepafenac ophthalmic solution 0.1% (DRUG), Ketorolac Tromethamine ophthalmic solution 0.4% (DRUG), Nepafenac ophthalmic suspension vehicle (OTHER).
Who is sponsoring clinical trial NCT00332774?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.